Long-Term Safety and Antihypertensive Effects of Renal Denervation: Current Insights

Klevin Roger L Reyes, Florian Rader Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USACorrespondence: Florian Rader, Hypertension Center of Excellence, 127 San Vincente Blvd. AHSP A3408, Los Angeles, CA, 90048, USA, Tel +1 310 423-3880, Fax +1 310 967-3805, Email Florian.Rader@...

Full description

Saved in:
Bibliographic Details
Main Authors: Reyes KR (Author), Rader F (Author)
Format: Book
Published: Dove Medical Press, 2023-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_60f0e81a687046b68c72ee858edbbe6d
042 |a dc 
100 1 0 |a Reyes KR  |e author 
700 1 0 |a Rader F  |e author 
245 0 0 |a Long-Term Safety and Antihypertensive Effects of Renal Denervation: Current Insights 
260 |b Dove Medical Press,   |c 2023-09-01T00:00:00Z. 
500 |a 1178-7104 
520 |a Klevin Roger L Reyes, Florian Rader Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USACorrespondence: Florian Rader, Hypertension Center of Excellence, 127 San Vincente Blvd. AHSP A3408, Los Angeles, CA, 90048, USA, Tel +1 310 423-3880, Fax +1 310 967-3805, Email Florian.Rader@cshs.orgAbstract: Hypertension is the most potent modifiable risk factor for the development of cardiovascular morbidity and mortality worldwide. Nevertheless, blood pressure (BP) control on a broad scale appears to be insurmountable and has even worsened in the US. Barriers to sustained hypertension control are multifactorial and although lack of patient awareness and socioeconomic barriers to healthcare access may play a role, medication non-compliance and therapeutic inertia are major causes. Renal denervation (RDN) is a minimally invasive procedure that has been the subject of interest in clinical trials for more than a decade and although the first sham-controlled trial could not detect group difference between treated and untreated hypertensives, subsequent, better designed sham-controlled trials clearly demonstrated the BP lowering effect of RDN, as well as its safety. While to-date, RDN is not available for routine clinical practice, one major requirement for broad implementation is that the BP lowering effect is durable. Therefore, this review will summarize the available long-term data of the different RDN modalities with respect to both effectiveness and safety.Keywords: hypertension, renal denervation, device therapy, blood pressure device, resistant hypertension 
546 |a EN 
690 |a hypertension 
690 |a renal denervation 
690 |a device therapy 
690 |a blood pressure device 
690 |a resistant hypertension 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Integrated Blood Pressure Control, Vol Volume 16, Pp 59-70 (2023) 
787 0 |n https://www.dovepress.com/long-term-safety-and-antihypertensive-effects-of-renal-denervation-cur-peer-reviewed-fulltext-article-IBPC 
787 0 |n https://doaj.org/toc/1178-7104 
856 4 1 |u https://doaj.org/article/60f0e81a687046b68c72ee858edbbe6d  |z Connect to this object online.